effect overlay
activetrials
Multiple sclerosis
Multiple Sclerosis
PASS

A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
 

HREC: 2015.153
Principal Investigator: Dr Mark Marriott
Coordinator contact: Lisa Taylor
Funding: Commercial
Multiple sclerosis
Multiple Sclerosis
INTREPID

Biomarkers of motor performance in multiple sclerosis: 7T MRI study
 

HREC: 2015.144
Principal Investigator: Prof Trevor Kilpatrick
Coordinator contact: Dr Vivien Li
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
ANZ NMO Collaboration

Prevalence and incidence study of neuromyelitis optica in Australia and New Zealand with population based sensitivity and specificity of NMO IgG antibody positivity
 

HREC: 2010.278
Principal Investigator: Dr Mark Marriott
Coordinator contact:
Funding: Non-Commercial
Movement Disorders
Movement Disorders
APM002

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson's Disease
 

HREC: 2024.061
Principal Investigator: Dr Andrew Evans
Coordinator contact: Reena Chopra
Funding: Non-Commercial
Movement Disorders
Movement Disorders
CYPRESS

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
 

HREC: 2023.188
Principal Investigator: Dr Andrew Evans
Coordinator contact:
Funding: Commercial